Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Future studies are expected to clarify whether GLP-1 RA deserve an adjunct place in the arsenal of drugs against IBD
Patients with a history of pancreatitis, gallbladder disease, multiple endocrine neoplasia syndrome type 2 (MEN 2), or of medullary thyroid cancer are generally not considered good candidates for Semaglutide GLP-1
This mirrors the semaglutide profile, where the FDA label for Ozempic states no dose adjustment for renal impairment
These novel compounds may provide synergistic benefits while minimizing systemic estrogen exposure, potentially revolutionizing treatment approaches for this population
A version of this story originally appeared in the Good News newsletter
Summary: Mounjaro (tirzepatide) can generally be taken after gallbladder removal, as there is no absolute contraindication for post-cholecystectomy patients
US$ 20.37
US$ 22.80
US$ 28.95
US$ 24.70
